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The mechanism whereby whole-cell pertussis vaccines (WCV) confer protection against Bordetella pertussis is
still not fully understood. We have previously reported that macrophage activation produced by vaccination
with WCV is associated with induction of NO synthesis by macrophages in response to in vitro stimulation with
B. pertussis antigens. To determine whether NO production is an effector of protection or simply a marker of
activation, the susceptibility of inducible nitric oxide synthase (type II, iNOS) knockout mice to infection with
B. pertussis was examined. We showed that iNOS knockout mice were more susceptible to B. pertussis respi-
ratory challenge than wild-type mice. iNOS-deficient mice also developed a less effective protective response
than wild-type mice after the same immunization with WCV. This suggests that NO plays an important role
in effecting protection against B. pertussis challenge.
Bordetella pertussis is a human pathogen which possesses
tropism for the respiratory system, causing an acute and some-
times persistent disease. Although pertussis vaccines have been
in use for mass vaccination in most countries for many years
and have led to a major decrease in the incidence of pertussis,
the mechanism by which they induce protection against per-
tussis in children is still unclear. Recent evidence indicates that
B. pertussis is a facultatively intracellular organism and that
clearance involves activated macrophages (4, 15, 20, 21). The
mechanism whereby macrophage activation results in the kill-
ing of facultatively intracellular pathogens is still incompletely
determined. However, it has become increasingly apparent in
recent years that NO and reactive nitrogen intermediates (ni-
trite and peroxynitrite) are potentially important mediators of
the immune system (1). Production of NO by activated murine
macrophages has been implicated as an antimicrobial effector
mechanism against several pathogens (2, 5, 9). We have re-
ported previously that macrophage activation produced by vac-
cination with a whole-cell pertussis vaccine (WCV) is associ-
ated with induction of NO synthesis by macrophages in
response to in vitro stimulation with B. pertussis antigens (20).
The presence of small quantities of active pertussis toxin seems
to be important for this process (21). The relationship between
NO induced in macrophages in response to in vitro culture
with bacterial antigens and protection in vivo in the mouse
intracerebral challenge model indicates that macrophage acti-
vation is involved in protective immunity (20). However, it is
not clear from these studies whether NO is an effector of
protection or simply a coincidental marker of activation.
To clarify further the role of NO in protection against B.
pertussis challenge, the induction of NO synthesis by macro-
phages and protection in vivo against aerosol challenge in-
duced by a conventional WCV and the new-generation acel-
lular pertussis vaccine (ACV) was investigated in inducible
nitric oxide synthase (iNOS)-deficient mice.
MATERIALS AND METHODS
Vaccines. A WCV (National Institute for Biological Standards and Control
[NIBSC] reagent 88/522, 3rd British Reference Preparation; potency, 50 IU/
ampoule) (14) and a commercially available three-component ACV containing
25 g of pertussis toxoid (PT) chemically detoxified with formaldehyde and
glutaraldehyde, 25 g of filamentous hemagglutinin (FHA), and 8 g of pertac-
tin (PRN) per single human dose (SHD), in combination with diphtheria and
tetanus toxoids (DTPa), was used for the immunization. All other reagents were
of analytical grade.
Animals. iNOS-deficient mice and their wild-type littermates were generated
as described previously (17). The murine iNOS gene was disrupted by homolo-
gous recombination in 129sv embryonic stem (ES) cells. The recombinant allele
was passed through the germ line following mating of ES cell chimeras with 129sv
(Harlan UK Ltd., Oxford, United Kingdom). The homozygous, heterozygous,
and wild type littermates of the 129sv strains were used at the ages of approxi-
mately 3 to 4 weeks.
Immunogenicity study. Groups of five mice were immunized (intraperitoneally
[i.p.]) with ACV at 0.25 SHD per dose and with WCV at 0.125 IU per dose
(which is equivalent to approximately 0.03 SHD), and both vaccines were diluted
in phosphate-buffered saline (PBS). Mice in the control group received PBS.
Mice were terminally bled at 4 weeks postimmunization, and sera from individual
animals were assayed for total immunoglobulin G (IgG) antibodies to the B.
pertussis antigens PT, FHA, and PRN by a standard enzyme-linked immunosor-
bent assay (ELISA). The geometric mean ELISA units (EU) of the antibody to
each antigen were calculated against the First World Health Organization
(WHO) International Reference Anti-B. pertussis Serum (Mouse) (19). All the
serum samples were always analyzed in parallel with the reference antiserum on
the same plate. Relative concentrations of IgG1 and IgG2a specific for the B.
pertussis antigens PT, FHA, and PRN were measured by using sheep anti-mouse
IgG subclass-biotin and horseradish peroxidase-avidin conjugates (PharMingen)
(11). Specific responses for each subclass were presented as the ratio of the
optical density at 492 nm (OD492) of the test sample to the OD492 of the
reference serum used in each plate.
Bacterial antigens. Heat-killed B. pertussis 18.323 cells (HKC) were prepared
by incubation of bacterial cells (5  109/ml) in PBS at 80°C for 30 min (20).
Purified detoxified PT, FHA, and PRN were kindly provided by GlaxoSmithK-
line, Rixensart, Belgium.
Macrophages. Mice were immunized with WCV or ACV at the indicated
doses. Control mice received PBS. Macrophage cultures were prepared accord-
ing to the method described by Torre et al. (16). In brief, mice were terminally
bled on the indicated day postimmunization. The peritoneal cavity was then
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lavaged with sterile PBS to recover macrophages. Cells were pooled from groups
of 6 to 10 mice and recovered by centrifugation. Cell pellets were resuspended in
RPMI 1640 medium with L-glutamine supplemented with 10% fetal calf serum,
1% penicillin, and 1% streptomycin, placed in 24-well tissue culture plates at 2
 106 cells per well, and incubated at 37°C under 5% CO2 in 90% humidity for
2 h. Cells were washed three times with RPMI 1640 medium to remove nonad-
herent cells.
Culture of macrophages and determination of nitrite production. Macro-
phages were cultured in a total volume of 1 ml/well with 2  106 HKC/ml.
Cultures were incubated at 37°C under 5% CO2 in 90% humidity for 24 h. Cell
viability was checked by trypan blue exclusion before and after incubation.
Nitrite determinations were made on 50 l of sample mixed with 50 l of the
Griess reagent (16), and the A540 was measured using an Anthos ELISA Reader
(Life Sciences International, Basingstoke, United Kingdom).
In vivo aerosol challenge. Bacterial suspensions (B. pertussis 18.323), stored at
70°C in 5% glycerol, were spread on charcoal agar plates (charcoal agar base
plus 10% defibrinated horse blood) and incubated at 37°C for 2 days. Two
further subcultures were performed with incubation for 16 to 18 h under the
same conditions. Bacterial cells were harvested and resuspended in 0.9% saline
containing 1% casein and adjusted to an OD623 of 0.2 by using a spectropho-
tometer (MSE-Fisons, Loughborough, United Kingdom). The suspension was
kept on ice until it was used for aerosol challenge. Aerosol challenge was
performed on groups of five previously immunized mice that were exposed to B.
pertussis 18.323 for 5 min by use of a custom-made aerosol apparatus (22). The
lungs and tracheas were removed from each group at the indicated time point
after challenge and were homogenized in 1 ml of 1% casein solution by means of
a mini-bead beater using 2.5- to 3.5-mm-diameter glass balls. Viable counts were
then performed on the homogenate by diluting across microtiter plates and
plating onto charcoal agar plates. The mean viable count per lung from five mice
was taken as the CFU per lung.
Statistical analysis. Data obtained from immunized subjects were compared
with those for other groups by the Student t test in order to determine the
statistical significance of differences between two groups. P values below 0.05
were regarded as statistically significant.
RESULTS
The time course of B. pertussis infection in wild-type and
mutant mice was investigated by aerosol challenge on naive
mice, and CFU counts in their lungs were taken at indicated
time points (Fig. 1). Replication of the organisms resulted in
similar increases in the numbers of bacteria recoverable from
the two groups of mice, approximately 2.5 to 3.0 log units by
day 7 to 10. However, bacterial counts subsequently declined
more rapidly in wild-type mice than in iNOS knockout mice.
Thus, by day 18, bacterial counts in iNOS-deficient mice were
at least 0.5 log unit higher than those in wild-type mice, and
this difference (P  0.05) was maintained until the end of the
experiment.
To assess the ability of murine peritoneal macrophages to
generate NO in response to in vitro stimulation with HKC,
mice were immunized with WCV or ACV. The peak time for
production of NO in the macrophage cultures was approxi-
mately 10 to 15 days postimmunization (data not shown).
Therefore, in this study all macrophages were isolated from
mice on day 15 post immunization.
Peak NO concentrations in macrophage cultures from the
wild type group were approximately threefold higher than
those from the mutant group. Furthermore, macrophages from
mice lacking iNOS produced lower NO concentrations in their
cultures after in vitro restimulation with HKC than cells re-
covered from wild-type mice (Fig. 2a). This corresponded
closely to the resistance to aerosol challenge observed in vivo
in the two types of mice (Fig. 2b), where the CFU count per
lung was approximately 2 log units lower in wild-type than in
mutant mice.
Macrophages from mice immunized with ACV were also
assayed for NO production with and without the addition of
HKC. Unlike those from mice immunized with WCV, macro-
phages from mice immunized with ACV did not produce NO
concentrations higher than those for the control group before
the stimulation in vitro (baseline) (Fig. 3a). However, these
macrophages were able to produce NO in response to B. per-
tussis HKC stimulation, although the levels were lower than
those for the WCV-immunized group. NO concentrations in
cultures from the wild-type group were more than threefold
higher than those in cultures from the homozygous group. This
also closely paralleled the pattern of in vivo protection against
aerosol challenge, where CFU counts in the lungs of the mu-
tant group were approximately 1.5 log units higher (P  0.05)
than those in the lungs of the wild-type group (Fig. 3b).
To investigate the relationship of the NO produced by acti-
vated macrophages to host defense against B. pertussis chal-
lenge, different immunization doses were used. Figure 4a
shows that the synthesis of NO by macrophages in response to
HKC restimulation was immunization dose dependent, and
again, macrophages from the wild-type group had higher NO
production than those from the mutant group. It was noted in
the protection study that when mice were immunized with
WCV at 1.0 IU/dose, similar reductions (of approximately 2.5
to 3.0 log units) in lung CFU counts occurred in both wild-type
and mutant groups in comparison with the control group (Fig.
4b). This was in spite of the fact that cells from wild-type mice
produced higher NO levels in their cultures than those from
the mutant group. Reduction of the immunization dose from
1.0 to 0.25 IU resulted in different protection profiles for these
two groups of mice, which corresponded with the NO concen-
trations achieved in their macrophage cultures. That is, the
mutant mice showed a lower level of protection than the wild-
type mice.
To investigate further the cellular and humoral immune
responses induced by immunization of these two types of mice
with WCV and ACV, pertussis-specific antibody production,
FIG. 1. Time course of infection. Groups of wild-type (F) and
mutant (Œ) mice were aerosol infected with B. pertussis 18.323. Lungs
from five mice in each group were sampled, and viable counts were
performed by four replicates. Each data point represents the mean
CFU per lung. Error bars, standard deviations.
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macrophage activation, and in vivo protection were assessed 4
weeks after immunization. Macrophages from both wild-type
and mutant mice immunized with WCV produced approxi-
mately 5.5-fold-higher NO concentrations in their cultures af-
ter stimulation with HKC than macrophages from the ACV-
immunized group (P  0.05) (Fig. 5a). The NO concentration
in macrophage cultures from the mutant group immunized
with WCV was approximately half that for the wild-type group.
There was no difference (P  0.05) in NO induction between
the mutant group immunized with ACV and the control group.
Titers of antibody to PT, FHA, and PRN (69 kDa) were
much higher in the ACV group than in the WCV group (Table
1). The ratio of IgG1 to IgG2a showed that mice immunized
with WCV gave a response shifted towards Th1, whereas those
immunized with ACV gave a response biased towards Th2. No
difference in antibody production was found between wild-type
FIG. 2. (a) Ability of murine peritoneal macrophages to generate NO in response to HKC. Mice were immunized with WCV at 0.25 IU/dose,
and macrophages were taken on day 15 postimmunization. Open bars, cells from control mice; solid bars, cells from immunized mice without
stimulation in vitro; crosshatched bars, cells from immunized mice stimulated with HKC in vitro. Data are means  standard deviations (n  3).
Cultures were incubated at 37°C for 24 h. (b) Response to aerosol challenge by groups of five mice immunized with PBS (open bars) or with WCV
at 0.25 IU/dose (solid bars). Mice were aerosol challenged on day 15 after immunization. Mouse lungs were removed at day 7 after the challenge.
Viable counts per lung were performed on four replicates. Bars represent mean CFU per lung; error bars, standard deviations.
FIG. 3. (a) Ability of murine peritoneal macrophages to generate NO in response to B. pertussis (HKC). Mice were immunized with 0.25 SHD
of ACV. Macrophages were collected on day 15 postimmunization. Open bars, cells from control mice stimulated with HKC in vitro; solid bars,
cells from immunized mice in the absence of stimulant; crosshatched bars, cells from immunized mice stimulated with HKC in vitro. Data are
means  standard deviations (n  3). Cultures were incubated at 37°C for 24 h. (b) Response to aerosol challenge by groups of five mice
immunized with PBS (open bars) or ACV at 0.25 SHD (solid bars). Mice were aerosol challenged on day 15 after immunization. Mouse lungs were
removed at day 7 after the challenge. Viable counts per lung were performed on four replicates. Bars represent mean CFU per lung; error bars,
standard deviations.
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and mutant mice immunized with WCV. However, among
mice immunized with ACV, lower levels of antibodies to FHA
and PRN were observed in the mutant group than in the
wild-type group. Aerosol challenge of mice at 4 weeks after
immunization showed that mice immunized with WCV had
developed better protection (P  0.05) than mice immunized
with ACV despite higher antibody responses developing in the
latter group (Fig. 5b). Comparison of wild-type mice and mu-
tant mice showed that the former group were better protected
from the challenge than the latter group (P  0.05) when
immunized with WCV or ACV.
DISCUSSION
Infection by B. pertussis, usually manifesting as pertussis
(whooping cough), is still an important cause of morbidity and
mortality among children in many parts of the world (18). It is
also being recognized increasingly as a significant agent of
respiratory disease in adults (Editorial, Lancet 339:526–527,
1992). The results of recent clinical trials have indicated that
both established WCVs and the new generation of ACVs can
stimulate protection in children (6, 7). We have previously
reported that macrophage activation produced by vaccination
FIG. 4. (a) Effect of immunization dose on NO induction by murine peritoneal macrophages taken from groups of five wild-type (open bars),
heterozygous (solid bars), and mutant (crosshatched bars) mice at 2 weeks after immunization with WCV at the indicated dose and stimulated with
HKC. All cultures were incubated at 37°C for 24 h. Bars represent means of triplicate cultures; error bars, standard deviations. (b) Effect of
immunization dose on protection in groups of five wild-type (open bars), heterozygous (solid bars), and mutant (crosshatched bars) mice at 2 weeks
after immunization with WCV at the indicated dose. All mice were challenged by aerosol exposure to B. pertussis.
FIG. 5. (a) Ability of murine peritoneal macrophages to generate NO in response to HKC. Mice were immunized with PBS (open bars), 0.25
SHD of ACV (solid bars), or 0.125 IU of WCV (crosshatched bars). Four weeks later, macrophages were stimulated with HKC in vitro. Data are
means  standard deviations (n  3). Cultures were incubated at 37°C for 24 h. (b) Response to aerosol challenge by groups of five mice
immunized with PBS (open bars), ACV at 0.25 SHD (solid bars), or WCV at 0.125 IU (crosshatched bars). Mice were aerosol challenged at 4 weeks
after immunization. Mouse lungs were removed at day 7 after the challenge. Viable counts per lung were performed on four replicates. Bars
represent mean CFU per lung; error bars, standard deviations.
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with WCV is associated with induction of NO synthesis by
macrophages in response to in vitro stimulation with B. pertus-
sis antigens (20, 21). In the present study, iNOS knockout mice
were used to further examine the role of NO in protection
from B. pertussis respiratory challenge.
It has been reported previously that iNOS-deficient mice
produced more gamma interferon (IFN-	) and less interleukin
4 than similarly treated intact mice following infections and
antigenic stimulation (10, 12, 13). In the present study, the
results showed that elimination of B. pertussis from the lungs of
infected iNOS knockout mice was slower than elimination
from the lungs of wild-type mice after respiratory challenge.
The iNOS-deficient mice also showed a lower level of protec-
tion than the wild-type mice following the same immunization
with WCV or ACV in spite of producing a greater IFN-	
response to the bacterial antigens in vitro (data not shown).
This provides a further indication that NO is an important
effector molecule in protection against B. pertussis challenge.
Macrophages from wild-type and mutant mice immunized
with the WCV all produced NO in response to in vitro stimu-
lation with bacterial cells. This suggests that this type of vac-
cine is a very powerful inducer of NO synthase even in iNOS-
deficient mice. That the latter still produced some NO in spite
of the gene disruption may be attributable to the operation of
compensatory mechanisms through other pathways. Constitu-
tive NOS may also have contributed a background level of NO.
It should be noted that the iNOS gene-targeting construct was
produced by terminal extension and integration into the iNOS
gene. This disrupts the gene and should prevent expression but
may not completely eliminate it (3, 8). In the present study,
these mice produced substantially less NO than wild-type mice.
However, NO may not be the only effector of protection. It was
notable that when mice were immunized with higher doses of
the vaccine, there was no difference in protection between
wild-type and mutant mice, even though the wild-type mice
produced more NO in their macrophage cultures. This may
have been because the high vaccine doses stimulated an ade-
quate NO response in the knockout mice and the greater
amount produced by the wild-type mice added nothing further
to protection, or it may suggest that at high vaccine doses
another mechanism comes into play which is not dependent on
the bactericidal action of NO.
Macrophages isolated from mice immunized with WCV pro-
duced larger amounts of NO than those from the control group
without additional stimulation. Our previous studies showed
that this NO production was increased by adding HKC but not
by IFN-	 and that NO induced by HKC was only partially
blocked by concentrations of anti-IFN-	 which completely
blocked NO production in control cell cultures (20). Taken
together, these results suggested that these macrophages had
already been activated in vivo. It is noteworthy that macro-
phages from mice immunized with ACV did not produce NO
in vitro in the absence of stimulant. However, NO production
was significantly increased by the addition of HKC, and this
was clearly associated with protection in vivo. These results
suggested that there might be a difference in the degree of
macrophage activation produced in vivo by immunization with
these two different types of vaccines. Furthermore, mice im-
munized with ACV produced lower IFN-	 levels (data not
shown) in culture than those immunized with WCV after stim-
ulation in vitro. This may indicate that mice immunized with
WCV developed a stronger Th1 type response than those that
received ACV.
Although pertussis vaccination is used throughout the world
and has made a major contribution to decreasing morbidity
and mortality from pertussis, its precise mode of action is still
unclear. There is, however, increasing recognition of the im-
portance of cell-mediated immunity in protection against B.
pertussis. The present study using iNOS knockout mice has
provided direct evidence that the reactive nitrogen intermedi-
ates play an important role in the immune response induced by
both WCV and ACV and that this is associated with protective
immunity in vivo . This adds further weight to the hypothesis
that activation of the killing mechanisms of macrophages helps
to eliminate intracellular B. pertussis and hence to clear infec-
tion.
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